Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 15,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
11,400 registered articles
(updated on March 28, 2024)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
2.0
2022 Journal Impact Factor (JIF)
JOURNAL PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Scopus Pubmed
Featured article
Volume 47 (2024) Issue 2 Pages 509-517
Identification and Characterization of Synaptic Vesicle Membrane Protein VAT-1 Homolog as a New Catechin-Binding Protein Read more
Editor's pick

(-)-Epigallocatechin-3-gallate (EGCg) is known to upregulate neprilysin, an Aβ-degrading enzyme. To clarify the mechanism underlying this process, the authors screened catechin-binding proteins by pull-down assay with magnetic beads and LC-tandem mass spectrometry and identified synaptic vesicle membrane protein VAT-1 homolog (VAT1). Surface plasmon resonance analysis revealed a direct binding of recombinant VAT1 protein to EGCg or its alkylated derivative NUP-15 with comparable affinity to the other EGCg binding proteins reported previously. Furthermore, the authors found that VAT1 prevented the upregulation of neprilysin by EGCg or NUP-15 through binding to and inactivating them in the cells overexpressing VAT1.

Volume 47 (2024) Issue 2 Pages 462-468
Low Atmospheric Oxygen Attenuates Alpha Oscillations in the Primary Motor Cortex of Awake Rats Read more
Editor's pick

The authors investigated concurrent effects of hypoxia on physiological signals by simultaneously recording local field potentials in the primary motor, primary somatosensory and anterior cingulate cortices as well as electrocardiograms, electroolfactograms, and electromyograms of rats in acutely hypoxic environment. When they were exposed to acute hypoxia, alpha oscillations in the primary motor cortex were impaired. Moreover, the authors demonstrated that heart rate and respiratory rate were increased during acute hypoxia and high heart rate was maintained even after the oxygen level returned to the baseline. Altogether, this study characterizes a systemic effect of atmospheric hypoxia from physiological viewpoints.

Volume 47 (2024) Issue 2 Pages 443-448
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn’s Disease Patients Who Failed Anti-tumor Necrosis Factor-α Treatment in Japan: An Observational Study Utilizing Claims Database Read more
Editor's pick

This study examined whether the approved sequence of vedolizumab and ustekinumab impacts the results of studies conducted in the EU, comparing the effectiveness of these drugs in Crohn's disease (CD) patients who failed anti-TNFα treatment. The authors conducted this study in Japan, where the approved sequence of drugs is different from that of the EU. They analyzed data from 256 CD patients from the Japanese claims database. The results suggested that ustekinumab is a more effective treatment option than vedolizumab for CD patients who failed anti-TNFα treatment, and this finding remains consistent across both Japan and the EU.

Volume 47 (2024) Issue 2 Pages 399-410
Icariin Regulates EMT and Stem Cell-Like Character in Breast Cancer through Modulating lncRNA NEAT1/TGFβ/SMAD2 Signaling Pathway Read more
Editor's pick

[Highlighted Paper selected by Editor-in-Chief]
Icariin(ICA) affects the EMT and cancer stem cell-like character of breast cancer cells. The main mechanism is to influence the characteristics of EMT and cancer stem cell-like character of breast cancer cells by regulating the TGFβ/SMAD2 signaling pathway, which in turn affects the migration of breast cancer cells. In addition, we have found not only ICA inhibits proliferation, EMT and stem cell-like character of breast cancer cells by silencing lncRNA NEAT1, but NEAT1 can exert anti-breast cancer effects through TGFβ/SMAD2 signaling pathway. Overall, we hypothesized that ICA could inhibit the proliferation, EMT and cancer stem cell-like character of breast cancer cells through the NEAT1/TGFβ/SMAD2 axis and suppress breast cancer migration.

Volume 47 (2024) Issue 2 Pages 345-349
A Novel Strategy for the Discovery of Drug Targets: Integrating Clinical Evidence with Molecular Studies Read more
Editor's pick

Recently, large amount of real-world data (RWD), such as insurance claims data and self-reports of adverse drug reactions become available. Statistical analysis of RWD has made it possible to identify novel and unexpected confounding factors that influence the occurrence of adverse events or spontaneous disease in humans. Such drug-drug interactions lead to the elucidation of adverse event mechanisms and the discovery of new drug targets. In addition, hypotheses derived from RWD may have high clinical predictive value. In this review, the author shows how RWD analysis can lead to the discovery of drug targets, by introducing examples of research reports.

View all featured articles
Most viewed articles (February 2024)
Share this page
Browse by volume and issue
feedback
Top